USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20240101700A1
SERIAL NO

18335542

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention discloses a key mechanism of action of itolizumab that involves a decrease in an activating ALCAM-CD6 co stimulatory signal by directly reducing CD6 hyperphosphorylation and preventing the docking of key molecules associated with T cell activation and signaling.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BIOCON LTDBANGALORE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
BUGHANI, Usha Bangalore, IN 7 16
MELARKODE, Ramakrishnan Bangalore, IN 25 124
NAIR, Pradip Bangalore, IN 20 79
SADASHIVARAO, Ravindra Belavinakodige Karnataka, IN 4 7
SAHA, Arindam Bangalore, IN 20 254

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation